Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

Experts discuss the evolving role of PD-L1 in guiding perioperative treatment decisions for resectable NSCLC and review the ...

NImmune Biopharma ("NImmune"), a private late-stage precision inflammation and immunology ("I&I") biopharmaceutical company, today announced that Executive Chairman, President and CEO Dr. Josep ...

The FDA has rejected a rare blood disease candidate from Disc Medicine, a compound that been granted expedited review through ...

Disc Medicine stock is hit by an FDA CRL for bitopertin. Learn key trial risks, cash runway, and why APOLLO Phase 3 results ...

Israel’s Teva Pharmaceutical Industries US unit and French pharma major Sanofi today announced positive results from the RELIEVE UCCD long-term extension (LTE) study of duvakitug, an investigational ...

Early findings from the ongoing MIRACLE clinical trial suggest that the investigational drug annamycin, given with cytarabine, may help more patients with relapsed or refractory acute myeloid leukemia ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), and a clinical stage, leading global ...

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

USA: A recent analysis of the PROMISE randomized clinical trial suggests that measuring the volume and burden of coronary plaque may help predict major adverse cardiovascular events (MACE) ...

Intermittent Fasting Shows Limited Benefit for Overweight, Obese Adults: StudyA new review by Cochrane suggests that ...

Lunai Bioworks (NASDAQ: LNAI) has launched a new oncology collaboration with a clinical-stage partner to apply artificial intelligence to data from a randomized Phase 2 trial in metastatic colorectal ...